CNS Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
CNS Pharmaceuticals, Inc., a Nevada corporation and emerging growth company, filed this Current Report on Form 8-K on January 5, 2022. The filing discloses the entry into a Material Definitive Agreement for a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to sell the following securities to institutional investors:
- Common Stock: 9,489,474 shares.
- Pre-Funded Warrants: To purchase up to 2,615,790 shares (exercise price $0.001).
- Common Warrants: To purchase up to 12,105,264 shares (exercise price $0.82, expiring in 5 years).
- Offering Price: $0.95 per share of Common Stock (or Pre-Funded Warrant) plus accompanying Common Warrant.
- Gross Proceeds: Approximately $11.5 million (before fees and expenses).
The filing does not provide current revenue, profit, cash flow, or debt metrics as this is a transactional report rather than a periodic financial statement.
Material Changes and Use of Proceeds
This transaction represents a significant capital raise intended to fund clinical trials, preclinical programs, research and development activities, and general corporate purposes. The closing is expected on or about January 10, 2022, subject to customary conditions.
Guidance, Risks, and Contingencies
Placement Agent Fees: The Company engaged H.C. Wainwright & Co., LLC as the placement agent. Fees include:
- 7.0% of gross proceeds.
- Warrants to purchase 5.0% of the aggregate shares sold (605,263 warrants) at an exercise price of $1.1875 (125% of offering price).
- $50,000 for non-accountable expenses and $10,000 for legal fees.
Registration Rights: The Company agreed to file a resale registration statement by January 20, 2022, with an expected effectiveness date of March 21, 2022, assuming full review by the SEC.
Risks: The securities are sold unregistered under Section 4(a)(2) and Rule 506 of Regulation D. Representations in the Purchase Agreement are for the benefit of the parties and may not reflect current facts or materiality standards for public investors.
Investor Verification Checklist
- Verify the actual closing date and final gross proceeds received.
- Confirm the effective date of the resale registration statement.
- Review the impact of the new share issuance on existing shareholder dilution.
- Monitor the Company's cash burn rate relative to the $11.5 million raised to assess runway for clinical trials.